BVX - Bovie Medical Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
6.48
+0.07 (+1.09%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close6.41
Open6.49
Bid0.00 x 1000
Ask0.00 x 2200
Day's Range6.35 - 6.71
52 Week Range2.28 - 7.70
Volume129,549
Avg. Volume204,770
Market Cap215.159M
Beta (3Y Monthly)N/A
PE Ratio (TTM)3.27
EPS (TTM)N/A
Earnings DateMar 11, 2019 - Mar 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.88
Trade prices are not sourced from all markets
  • Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan
    Zacks2 months ago

    Conatus (CNAT) Focuses on Developing NASH Candidate Emricasan

    Conatus (CNAT) concentrates on the development of its lead candidate emricasan for treating patients with fibrosis or cirrhosis caused by NASH.

  • Has Bovie Medical (BVX) Outpaced Other Medical Stocks This Year?
    Zacks2 months ago

    Has Bovie Medical (BVX) Outpaced Other Medical Stocks This Year?

    Is (BVX) Outperforming Other Medical Stocks This Year?

  • Business Wire2 months ago

    Bovie Medical Corporation Files 510(k) Submission with the FDA for a New Indication to Market and Sell J-Plasma/Renuvion for Use in Dermal Resurfacing Procedures

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, today announced a Premarket Notification 510(K) submission to the U.S. Food and Drug Administration (FDA) for a new indication for J-Plasma/Renuvion for use in dermal resurfacing procedures. “We are pleased to announce this 510(K) submission requesting clearance for a new clinical indication to market and sell our Renuvion Cosmetic Technology for dermal resurfacing procedures, which represents another important step towards our strategic objective to expand Renuvion’s clinical indications for use in the cosmetic surgery market,” said Charlie Goodwin, Chief Executive Officer.

  • Business Wire2 months ago

    Bovie Medical Corporation Announces Appointment of Tara H. Semb as Chief Financial Officer

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, today announced the appointment of Tara H. Semb as Chief Financial Officer, effective January 2, 2019. “I am pleased to announce the appointment of Tara Semb, who joins the executive leadership team at Bovie Medical with a strong background in financial and operational business process and internal controls,” said Charlie Goodwin, President and Chief Executive Officer. “Ms. Semb’s career history includes executive level experience as the Chief Financial Officer for a rapidly growing company in the consumer market, and she has also held senior positions on the finance team at a large, diversified global manufacturing company with significant commercial scale and profitability.

  • Business Wire2 months ago

    Bovie Medical Corporation Announces Corporate Name Change to Apyx Medical Corporation and Plans to Transition Common Stock Listing to NASDAQ Global Select Market

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, today announced a corporate rebranding and company name change to Apyx Medical Corporation effective January 1, 2019. The Company also announced plans to move its stock exchange listing to the NASDAQ Global Select Market (the “NASDAQ”) from the New York Stock Exchange (the “NYSE”). The Company expects that its common stock will commence trading on the NASDAQ Global Select Market on January 2, 2019, under a new ticker symbol – “APYX”.

  • Zacks2 months ago

    Quidel (QDEL) Catches Eye: Stock Jumps 6.7%

    Quidel (QDEL) shares rose nearly 7% in the last trading session, amid huge volumes.

  • Zacks2 months ago

    Why Varex Imaging (VREX) Could Be Positioned for a Slump

    Varex Imaging (VREX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

  • GuruFocus.com2 months ago

    5 Stocks Join Ben Graham Net-Net Screener in Market Decline

    Stocks becoming more attractive buys

  • Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study
    Zacks2 months ago

    Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study

    Conatus' (CNAT) emricasan fails to meet the primary endpoint in a phase IIb study on compensated NASH cirrhosis patients at high risk of decompensation.

  • Will Bovie Medical (BVX) Continue to Surge Higher?
    Zacks3 months ago

    Will Bovie Medical (BVX) Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Bovie Medical Corporation (BVX).

  • Business Wire3 months ago

    Bovie Medical Corporation Announces Future Retirement of Jay D. Ewers, Chief Financial Officer, Treasurer and Secretary

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that Jay D. Ewers, Chief Financial Officer, Treasurer and Secretary, intends to retire. The Company has initiated a search for a new Chief Financial Officer and Mr. Ewers is committed to remaining in his current role until a successor is found. “I would like to thank Jay, on behalf of the Board and the entire team at Bovie Medical, for his significant contributions since joining the Company in 2014,” said Charlie Goodwin, President and Chief Executive Officer.

  • What Makes Bovie Medical (BVX) a Strong Momentum Stock: Buy Now?
    Zacks3 months ago

    What Makes Bovie Medical (BVX) a Strong Momentum Stock: Buy Now?

    Does Bovie Medical (BVX) have what it takes to be a top stock pick for momentum investors? Let's find out.

  • Associated Press4 months ago

    Bovie: 3Q Earnings Snapshot

    On a per-share basis, the Clearwater, Florida-based company said it had profit of $1.98. Losses, adjusted to account for discontinued operations, came to 1 cent per share. The medical device maker posted ...

  • Business Wire4 months ago

    Bovie Medical Corporation Reports Third Quarter 2018 Financial Results and Updates Fiscal Year 2018 Outlook

    Advanced Energy Sales of $3.0 million in Q3, up 40% year-over-year and 92% year-to-date

  • Business Wire4 months ago

    Bovie Medical Corporation to Participate in the 9th Annual Craig-Hallum Alpha Select Conference

    Bovie Medical Corporation , a medical technology company and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that management will participate in the 9th Annual Craig-Hallum Alpha Select Conference at the Sheraton New York Times Square Hotel in New York, New York.

  • Business Wire4 months ago

    Bovie Medical Corporation Announces Appointment of Laura Iversen as Director of Global Operations for Advanced Energy

    Bovie Medical Corporation (BVX) (the “Company”), a medical technology company and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced the appointment of Laura Iversen as Director of Global Operations for Advanced Energy. “Bovie Medical is pleased to announce the appointment of Laura Iversen to this newly created leadership position, as we continue to focus on improving our manufacturing capabilities and efficiencies to accommodate the strong demand that we anticipate for our Advanced Energy products in the years to come,” said Charlie Goodwin, Chief Executive Officer of the Company.

  • Zacks.com highlights: WillScot, Primerica, Bovie Medical, Shenandoah Telecommunications and Herbalife Nutrition
    Zacks4 months ago

    Zacks.com highlights: WillScot, Primerica, Bovie Medical, Shenandoah Telecommunications and Herbalife Nutrition

    Zacks.com highlights: WillScot, Primerica, Bovie Medical, Shenandoah Telecommunications and Herbalife Nutrition

  • Snap Up These 5 Stocks on New Analyst Coverage
    Zacks4 months ago

    Snap Up These 5 Stocks on New Analyst Coverage

    Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.

  • Simply Wall St.4 months ago

    Are Bovie Medical Corporation’s (NYSEMKT:BVX) Interest Costs Too High?

    While small-cap stocks, such as Bovie Medical Corporation (NYSEMKT:BVX) with its market cap of US$213m, are popular for their explosive growth, investors should also be aware of their balance sheet Read More...

  • Implied Volatility Surging for Bovie Medical (BVX) Stock Options
    Zacks4 months ago

    Implied Volatility Surging for Bovie Medical (BVX) Stock Options

    Bovie Medical (BVX) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Do Options Traders Know Something About Bovie Medical (BVX) Stock We Don't?
    Zacks4 months ago

    Do Options Traders Know Something About Bovie Medical (BVX) Stock We Don't?

    Investors need to pay close attention to Bovie Medical (BVX) stock based on the movements in the options market lately.

  • Business Wire5 months ago

    Bovie Medical Corporation to Release Third Quarter of Fiscal Year 2018 Financial Results on November 1, 2018

    Bovie Medical (BVX), a medical technology company and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that financial results for the third quarter of fiscal year 2018 will be released after the market closes on Thursday, November 1. To listen to the call by phone, interested parties may dial 844-507-6493 (or 647-253-8641 for international callers) and provide access code 6375776. Participants should ask for the Bovie Medical Corporation Call.

  • Business Wire5 months ago

    Bovie Medical Corporation to Present at the Sidoti & Company Fall 2018 Investor Conference

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that management will participate in the Sidoti & Company Fall 2018 Investor Conference at the Grand Hyatt in New York, New York. A live audio webcast of the presentation will be provided under the ‘Company Events’ section of the Bovie Medical investor relations website at http://www.boviemedical.com/investor_relations/.

  • Business Wire6 months ago

    Bovie Medical Corporation Updates Fiscal Year 2018 Financial Outlook

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today updated financial guidance expectations for the twelve months ending December 31, 2018. The Company is introducing fiscal year 2018 financial guidance on a continuing operations basis as adjusted, which reflects the consummation of the Core segment sale transaction which closed on August 30, 2018. Total revenue from continuing operations in the range of $15.2 million to $15.6 million, representing growth of 49% to 53% year-over-year, compared to total revenue from continuing operations of $10.2 million in fiscal year 2017.